[HTML][HTML] The Onclarity human papillomavirus trial: design, methods, and baseline results
MH Stoler, TC Wright Jr, V Parvu, L Vaughan… - Gynecologic …, 2018 - Elsevier
Objectives The baseline phase of the Onclarity trial was conducted to determine the
screening performance of the Onclarity human papillomavirus (HPV) assay for detecting …
screening performance of the Onclarity human papillomavirus (HPV) assay for detecting …
Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review
Objective Thirteen human papillomavirus (HPV) genotypes are associated with the highest
risk of cervical disease/cancer; however, the risk of disease progression and cancer is …
risk of cervical disease/cancer; however, the risk of disease progression and cancer is …
[HTML][HTML] Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test
TC Wright, MH Stoler, CM Behrens, A Sharma… - Gynecologic …, 2015 - Elsevier
Objectives ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer
in women≥ 25 years. This reports the 3-year end-of-study results comparing the …
in women≥ 25 years. This reports the 3-year end-of-study results comparing the …
[HTML][HTML] Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women,≥ 25 years of age, with NILM cytology
MH Stoler, TC Wright Jr, V Parvu, K Yanson… - Gynecologic …, 2019 - Elsevier
Objectives Increasing evidence suggests that extended human papillomavirus (HPV)
genotyping (beyond 16/18) is effective for risk stratification in women with normal cytology …
genotyping (beyond 16/18) is effective for risk stratification in women with normal cytology …
The ATHENA human papillomavirus study: design, methods, and baseline results
TC Wright Jr, MH Stoler, CM Behrens, R Apple… - American journal of …, 2012 - Elsevier
OBJECTIVE: The objective of the study was to describe baseline data from Addressing the
Need for Advanced HPV Diagnostics, a prospective, multicenter US cervical cancer …
Need for Advanced HPV Diagnostics, a prospective, multicenter US cervical cancer …
Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the Becton Dickinson …
TC Wright Jr, MH Stoler, V Parvu… - American journal of …, 2019 - academic.oup.com
Objectives To determine clinical utility of Onclarity human papillomavirus (HPV) assay for
atypical squamous cells-undetermined significance (ASC-US) triage, and the value of HPV …
atypical squamous cells-undetermined significance (ASC-US) triage, and the value of HPV …
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting
M Leinonen, P Nieminen… - JNCI: Journal of the …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV) DNA testing has shown higher sensitivity
than cytology for detecting cervical lesions, but it is uncertain whether the higher sensitivity is …
than cytology for detecting cervical lesions, but it is uncertain whether the higher sensitivity is …
Human papillomavirus testing versus cytology in primary cervical cancer screening: End‐of‐study and extended follow‐up results from the Canadian cervical cancer …
SD Isidean, MH Mayrand… - … journal of cancer, 2016 - Wiley Online Library
The Canadian Cervical Cancer Screening Trial was a randomized controlled trial comparing
the performance of human papillomavirus (HPV) testing and Papanicolaou cytology to …
the performance of human papillomavirus (HPV) testing and Papanicolaou cytology to …
[HTML][HTML] The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1 …
M Safaeian, TC Wright Jr, MH Stoler… - American Journal of …, 2021 - Elsevier
Background An increase in human papillomavirus test volumes is expected in the near
future because human papillomavirus–based screening protocols are expected to become …
future because human papillomavirus–based screening protocols are expected to become …
Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices
AJ Blatt, R Kennedy, RD Luff, RM Austin… - Cancer …, 2015 - Wiley Online Library
BACKGROUND In the United States, human papillomavirus (HPV) and Papanicolaou (Pap)
testing (cotesting) for cervical screening in women ages 30 to 65 years is the preferred …
testing (cotesting) for cervical screening in women ages 30 to 65 years is the preferred …